How long on Wegovy before you start seeing results?

Why don't results show up in the first week or two?

When Wegovy treatment starts, the dose is 0.25mg, a starting point designed to let your digestive system adjust, not to deliver maximum appetite suppression. Nausea and other GI effects are common in these early weeks, and the medicine's effect on hunger is gentler at lower doses. The titration schedule moves upward roughly every four weeks, so by the time you reach the 1.7mg or 2.4mg level, the appetite-reducing effects of this GLP-1 receptor agonist are properly established.

That stepwise climb means the first month on treatment can feel underwhelming. A small number of people do see the scale shift early, often because reduced nausea and smaller portions add up quickly. For most, though, the first real momentum arrives somewhere between weeks four and eight, and if you want to understand when you start seeing results on Wegovy and why that window varies from person to person, that page goes into the detail. The NHS patient information for semaglutide notes that the titration schedule exists specifically to reduce side effects, and that the therapeutic benefit builds with the dose.

Practically speaking: if you store your pen in the fridge door alongside everyday items, the weekly injection becomes part of a routine rather than an event, and that consistency across the titration period is part of what allows results to accumulate.

When do most people see the clearest progress?

Months two through six are where the majority of trial participants showed the steepest rate of weight loss. By this point most people have reached or are approaching maintenance dose, appetite suppression is consistent, and the cumulative effect of eating less over many weeks becomes visible. The STEP 1 trial tracked 1,961 adults over 68 weeks and found average weight loss of around 15%, which works out to roughly 12–15kg for someone starting at 100kg. That didn't arrive in month one; the curve is gradual but persistent.

Progress tends to slow after the first six months, not because the medicine stops working but because the body adapts. Weight loss in the second half of treatment is typically smaller week-to-week but still real. Some people reach a new plateau; others continue losing steadily. Those who combine Wegovy with genuine changes to eating patterns and physical activity generally see better outcomes than those relying on the medicine alone, a point the NICE appraisal of semaglutide (TA875) emphasises throughout its recommendations. If you want to explore what drives the variation in how quickly results appear, this page looks at when you should start seeing results from Wegovy in more detail.

What if results seem slow or have stalled?

A plateau after several months is not the same as treatment not working. Weight loss slows as the body reaches a new equilibrium, and the comparison to early weeks can feel discouraging. A few things are worth considering before concluding that progress has stopped for good. Dose: if you're still on a lower dose because of tolerability, there may be scope to increase. Lifestyle: appetite suppression makes it easier to eat less, but it doesn't choose what you eat, protein adequacy, hydration and activity still matter. And consistency: missed doses or irregular timing affect the medicine's steady-state levels.

The six-month mark carries clinical weight. NICE guidance on Wegovy recommends that if a person has lost less than 5% of their starting weight after six months at the highest dose they've tolerated, continuing should be reviewed. This isn't a fixed cut-off that automatically ends treatment, but it is a meaningful checkpoint and a useful conversation to have with a prescriber. For questions about how long before you see results from Wegovy across the full duration of treatment, that page covers the overall working timeline from first dose through to longer-term maintenance. You can also read more about the broader Wegovy treatment overview if you're weighing up whether it's the right option for you. Understanding the cost context is equally useful; if you're comparing what private Wegovy treatment involves financially, our treatment page sets out what's included in a single transparent price.

Does the new 7.2mg dose change the picture?

In April 2026 the MHRA approved a dedicated single-dose 7.2mg Wegovy pen, a higher maintenance option that follows the same stepwise titration beginning at 0.25mg. Trial data for the 7.2mg dose reported around 20.7% average weight loss over 72 weeks, which narrows the gap with tirzepatide 15mg. This doesn't mean faster early results; the starting phase and titration schedule remain the same. What it means is that for people who tolerate and respond well to semaglutide, there is now a higher ceiling. Whether the 7.2mg dose is appropriate is a clinical decision made with your prescriber. If you want a broader look at how long before you see results on Wegovy and how the two licensed injectable options compare on timeline, you can also explore how long it takes to see results on Wegovy across the full course of treatment before heading to our weight-loss treatment overview as a useful starting point.

Wegovy is a prescription-only medicine. Starting treatment, adjusting doses and deciding when results are sufficient are decisions made with a clinician, not independently. Speak to our prescribers if you'd like to understand whether Wegovy could be suitable for you, consultations are free, and our GPhC-registered prescribers review every application the same day.